Biogen publishes Phase 3 adolescent EMPAVELI kidney data
Biogen said it published a prespecified Phase 3 VALIANT adolescent subgroup analysis in CJASN, reporting reductions in proteinuria and stabilized kidney function with EMPAVELI versus placebo in C3G or primary IC-MPGN.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.